B enzodiazepines are reportedly the most frequently prescribed psychotropic medication. Among adults in the United States and Canada, 3% to 4% are using BDZs at any one time. 1 About 100 million prescriptions are written per year. The European Study of the Epidemiology of Mental Disorders (commonly referred to as ESEMeD) investigated the use of ADs and BDZs in 21 425 respondents from 6 countries. In the nonhelp-seeking population, BDZs were used more commonly than ADs, while in the help-seeking population, with a 12-month prevalence of major depressive disorder or anxiety disorder, BDZs were used as commonly as ADs. 2 In an Australian study, 3 16% of the adults aged 65 years and older (n = 3970) had at least 1 BDZ prescription and the prescription prevalence increased with age.
BDZs' sedative, hypnotic, and anxiolytic properties are used for various psychiatric and medical conditions including anxiety disorders, sleep disorders, seizure disorders, movement disorders, and muscle spasticity. They are used in anaesthesiology and for the symptomatic treatment of agitation associated with other psychiatric and neurological disorders including psychotic, mood, and cognitive disorders. 4 In emergencies they are the preferred treatment of withdrawal from alcohol and sedative-hypnotics as well as agitation from stimulants.
Tolerance to sedative effects usually develops among people receiving maintenance therapy with a stable dose of BDZs; by contrast, the memory-impairing effects can persist after several years of daily administration. 5 Overdoses are almost never fatal unless occurring in combination with other sedative agents such as alcohol or opiates.
The reinforcing effects of BDZs may not only be mediated through binding of the alpha 1 or lambda 2 subtypes of GABA receptors but also via an opioid mechanism. A partial mu receptor antagonist such as naltrexone may reduce anxiolytic and positive subjective effects of BDZs. This may explain the high level of co-occurrence of BDZs and opioid dependence. Of interest, BDZs are the only major class of drugs with abuse liability that decrease dopamine levels in the mesolimbic system. 6
From Physiologic Dependence to Loss of Control
The dose and duration of exposure to BDZs determines the development of physiological dependence. It is almost never seen in patients treated for less than 2 weeks but occurs in about 50% of patients treated daily for more than 4 months. Short-and long-acting BDZs produce comparable severity of withdrawal. The development of physiological dependence is reduced with intermittent, compared with continuous, exposure to BDZs. Among people exposed to BDZs, a small subset, likely among those who have abused other substances, will develop compulsive drug-seeking behaviour with loss of control and an inability to stop. The same may apply to people with a positive family history of drug or alcohol dependence, given that some of the risk may be hereditary. 7 Most patients treated chronically with BDZs, who presumably may have physiological dependence, do not develop compulsive substance use, 8 and some patients present with compulsive substance use without physiological dependence. The abuse potential of BDZs depends not only on the drug receptor selectivity but also on the characteristics of the individual and environmental circumstances.
BDZs as a primary substance of abuse in people admitted for addiction treatment make up less than 1% of all admissions. Most of these people report abuse of alcohol or opioids in addition to BDZs. 9 The presence of another co-occurring psychiatric disorder (mood, anxiety, and Cluster C personality) occurs in up to 50% of these admissions. Among patients on methadone maintenance treatment, 40% to 50% abuse BDZs. These rates are not significantly reduced by methadone maintenance alone.
Guidelines for Responsible Prescription
APA and NICE. The APA guideline for the treatment of panic disorder 10 and the NICE guideline 11 on the management of panic disorder and GAD recommend SSRIs and not BDZs as the best choice of medication, alongside CBT and self-help based on CBT principles. BDZs are associated with a less good outcome in the long term and should not be prescribed beyond 2 to 4 weeks in GAD and are not recommended for panic disorder.
BDZs, Compared With non-BDZ Antianxiety Medication and
CBT. Non-BDZ antianxiety medication and CBT often take weeks before there is any beneficial effect, thus the short-term prescription of high-potency BDZs may remain an option when patients express an urgent need for the reduction of high levels of anticipatory anxiety and the reduction in the severity of panic attacks. BDZs with slower onset and longer action may be safer than fast-acting agents.
BDZs, Compared With SSRIs and SNRIs. In the case of comorbid anxiety and depression, SSRIs and (or) SNRIs are the first-line medication but BDZs may also provide benefits both for speed of response and for overall response. ADs should also be started early as the shorter the time elapsed between the onset of GAD and first adequate pharmacological treatment the better the prognosis. 12
Concerns Associated With the Prescription of BDZs
Concerns include: 1. BDZs mainly have a favourable side effect profile; however, patients, the elderly in particular, may experience sedation, fatigue, slurred speech, memory impairment, and weakness.
2. Even when the SSRI and (or) CBT has started to work, the patient may still believe that the BDZ is the effective agent and then have difficulty discontinuing it. Provided with short-term symptomatic relief, the patient may also lose motivation to follow all the CBT steps.
3. Even after a few weeks of BDZ treatment, some patients will experience withdrawal reactions on discontinuation similar to an anxiety relapse, resulting in their reluctance to discontinue the BDZ.
Identifying and Targeting High-Risk People
This includes: 1. Screening for sedative-hypnotic use through a nonthreatening personal and family history and possibly urine toxicology.
2. Regular monitoring for signs of abuse or dependence as well as concurrent abuse of alcohol or other drugs.
3. Individual reassessment of risks and benefits of prescription at regular intervals.
Reduction of physiological dependence, through:
· Use of adequate doses over a few weeks only.
· Drug holidays; that is, intermittent use of medication only in the case of high-anxiety situations, for example, in a GAD. 5. Differentiation of common physiological dependence, compared with rarer iatrogenic addiction.
The Management of Cessation of Use. Cessation requires a detailed understanding by the patient of the options involved. In our experience, it is critical for a fearful patient to perceive that he or she retains a measure of control over the process. Strategies for patients with comorbid anxiety or mood disorders and sedative-hypnotic use disorders will include: 1. Very gradual taper of medication during several months. Referring the patient to a website such as the Ashton manual 13 may be of help.
2. Conversion to, and stabilization on, equivalent dose of alternative BDZ with a slower onset and a longer duration of effect; that is, conversion from alprazolam to clonazepam.
Discontinuation of BDZ and stabilization on an
alternate GABAergic agent with a higher safety profile; that is, carbamazepine or valproate.
4. Implementation of CBT, typically for several weeks or months, helps the patient to recognize and manage symptoms of withdrawal and rebound anxiety, while helping the transition in developing symptom control and self-efficacy.
5.
In the case of recurrence of mood or anxiety problems that may or may not mimic withdrawal symptoms, alternate pharmacotherapy such as trazodone combined with CBT can improve the tolerability of medication change. The resumption of BDZs or a return to a higher dose is not recommended. Sleep disturbances have been alleviated by adding melatonin.
Patient With Primary Substance Use Comorbidity. Very often a pattern of polysubstance abuse is evident. Admission to an inpatient admission with a rapid 2-to 3-week detoxification followed by an abstinence-based outpatient treatment has been recommended. 13 To maintain the gains of detoxification, a relapse strategy is required to help further recovery, preferably with the help of psychosocial approaches including mutual help groups.
The Elderly. BDZs are still widely prescribed among the elderly, most of whom are women. 3 Both duration and cumulative exposure to BDZs may have negative effects on their cognitive performance and functioning in the community, and long-term prescriptions may lead to secondary driving problems as well as falls. There is a need to inform older adults about the risks of BDZs, offering effective discontinuation and managing their somatic, sleep, and anxiety problems by providing alternate pharmacological and psychological treatments.
Is BDZ Prescription a Necessary Evil?
Most BDZ users, particularly those with a comorbid psychiatric disorder, are receiving their medication from physicians, including psychiatrists, creating a unique opportunity for the medical profession to prevent the potential problems.
Practitioners feel both overwhelmed and empathic toward their patients' psychosocial problems and consider the prescription of BDZ as facilitating a coping strategy. Consulting psychiatrists may also perceive the prescription guidelines of BDZ as too narrow for complex cases. The answer may be in the diversification of more specific treatments for patients' refractory to current first-line recommendations. Long-term management plans must include strategies for acute or short-term care, long-term maintenance, and episodic or breakthrough symptoms. Although the statistical risk for dependence is relatively low, those unfortunate enough to develop it will experience a clinically challenging withdrawal course. Novel pharmacological factors, modulating particularly GABA receptors, ion channels, or glutamatergic transmission, are under various phases of investigation; their ease of discontinuation must also be assessed.
The implication is that newer medications with partial agonist effects at selected GABA receptor subtypes may result in more selective behavioural effects and better safety profiles.
BDZs Should Be Considered in the Long-Term Treatment of Mood and Anxiety Disorders
B enzodiazepines are one of the oldest classes of pharmaco-therapeutic medications. 1 Discovered in 1955 by Sternbach, they have been widely used in many areas of medicine. Most experts and regulatory guidelines recommend the short-term use of BDZs in the treatment of mood and anxiety disorders. 2 However, the long-term use of BDZs in treating mood and anxiety disorders has been controversial. Some have argued that the long-term use of BDZs will be associated with increased risk for tolerance, dose escalation, and dependence. 1 We argue here that the benefits of long-term BDZ use outweigh the potential adverse effects for most patients.
We suggest that there are 4 specific reasons to consider the use of BDZs as part of the overall treatment of mood and anxiety disorders. First, they work! BDZs rapidly, reliably, and robustly relieve anxiety symptoms and improve sleep. As there is clear evidence that mood and anxiety disorders are chronic, long-term conditions, there is often a relapse of symptoms when there is a reduction in dose or discontinuation of BDZs. This is sometimes interpreted as evidence that dependence has occurred (which may be the case) but the most parsimonious explanation is that the condition has not spontaneously remitted and further treatment is indicated. Second, the fear of dose escalation with BDZs, presumably Are There Guidelines for the Responsible Prescription of Benzodiazepines?
The Canadian Journal of Psychiatry, Vol 55, No 11, November 2010 W owing to tolerance, has been exaggerated. The little available evidence in this area suggests that a very small minority of patients have dose escalation (which could be due to tolerance). We will suggest some methods to minimize the risk of dose escalation. Third, BDZs are often better tolerated than SSRIs, atypical antipsychotics, or other classes of medications employed to treat anxiety that have side effects of weight gain and sexual dysfunction. Fourth, absence of recent evidence on the clinical usefulness of BDZs does not equal ineffectiveness. As there have been no new BDZs available on the market in the last 2 decades, there has been little financial motivation among pharmaceutical companies to conduct large-scale RCTs of BDZs in the treatment of mood and anxiety disorders. In summary, we suggest that clinicians need to carefully consider the use of BDZs in the long-term management of mood and anxiety symptoms, and researchers need to conduct large-scale RCTs in this area.
BDZs Are Efficacious
BDZs reduce anxiety symptoms among patients with primary anxiety disorders, and anxiety symptoms among patients with a mood disorder. The strongest evidence for the effectiveness of BDZs has been among patients with social phobia, GAD, and panic disorder. 3 RCTs have demonstrated that BDZs are effective in treating each of these anxiety disorders. There has been a dearth of studies that have examined the use of BDZs among patients with OCD 4 and PTSD. 5 Although the few studies examining the use of BDZs among patients with OCD and PTSD have not found strong evidence for their use, North American psychiatrists commonly use BDZs in the treatment of these conditions. 6, 7 In patients with mood disorders, anxiety symptoms often are substantial and associated with poor outcomes (for example, increased suicidality 8 and functional impairment). Some studies have shown that addition of regularly dosed (that is, not prn) clonazepam to ADs can accelerate the response among depressed patients, compared with those who receive ADs alone. 9 The treatment of anxiety symptoms among patients with bipolar disorder is especially important. However, as SSRIs may heighten the risk of mania and rapid cycling, we suggest that BDZs may be especially beneficial for these patients. There is a need for further study in this area.
The Dangers of Tolerance and Dependence on BDZs Have Been Catastrophized
Is a diabetic patient addicted to insulin? What about asthmatics; are they addicted to salbutamol? In our opinion, the dangers of developing tolerance and dependence on BDZs have been exaggerated. Long-term follow-up studies have shown that the incidence of dose escalation (a possible indicator of tolerance) occurs in only a small minority of patients. In a large population-based study 1 that followed over 2000 patients treated with BDZs for more than 2 years, the incidence of dose escalation was small (1.6%). Physical dependence on BDZs does, of course, occur in patients who have been taking therapeutic doses for any prolonged time period. This is to be expected, and is neither an indication of an untoward effect nor evidence of abuse or misuse. Some patients do abuse BDZs, and clinicians need to be wary of such people who are often expert at pulling the wool over prescribers' eyes. Patients who call for early refills, lose their medication and need a refill, or obtain their medication from multiple prescribers are to be carefully scrutinized in this regard. As clinicians, we need to use medications judiciously. Nonetheless, we should also make sure that we are treating patients adequately.
To minimize the small risk of dose escalation, we suggest that clinicians should consider the following. First, carefully assess a history of impulsivity (for example, concurrent or past alcohol and [or] substance use problem, antisocial personality disorder, and borderline personality disorder). Although anxiety symptoms and disorders are highly prevalent in these subgroups, our experience is that BDZs are not likely to be enormously helpful. Second, minimize the use of prn BDZs and use of short-half life BDZs (for example, alprazolam). As-needed use of short-term BDZs leads to a cycle of taking BDZs at the peak of anxiety. In our opinion, this cycle leads to a higher likelihood of dose escalation. Regular dose, long-acting BDZs such as clonazepam work well in treating anxiety symptoms without the risk of dose escalation.
BDZs Do Not Cause Sexual Dysfunction and Metabolic Syndrome
BDZs are well tolerated. However, SSRIs (and SNRIs) are associated with sexual dysfunction, and atypical antipsychotics are associated with metabolic syndrome and the risk (although smaller than for typical antipsychotics) of movement disorders. These side effects can have substantial negative consequences on intimate partner relationships and cardiovascular health. Moreover, they can have a substantially negative impact on adherence to treatment. BDZs are generally safe and well tolerated by patients.
Industry's Influence on BDZ Use?
We wonder whether one of the reasons for the lack of recent studies in this area is that there are no new BDZs on the market. All the BDZs are generic and there has been little financial incentive among pharmaceutical companies in conducting large-scale studies to examine the efficacy of BDZs among patients with mood and anxiety disorder. In contrast, marketing strategies and CME events sponsored by the pharmaceutical industry typically have highlighted the novelty of ADs and antipsychotics in treating mood and anxiety disorders over the less costly use of BDZs. Industrysponsored CME events that are focused on new treatments of mood and anxiety disorders often remind clinicians of the potential risk of tolerance and dependence of BDZs, and make a point of telling clinicians that BDZs are recommended only for short-term use by clinical practice guidelines.
An example of this issue is specifically in the treatment of GAD. Berney et al 10 reviewed the literature and found that there were 22 RCTs comparing ADs to BDZs. None of them showed superiority of ADs over BDZs in the treatment of GAD. They concluded that there has been a shift in prescribing ADs instead of BDZs for GAD without any evidence to support this shift.
In summary, judicious long-term use of BDZs should be thoughtfully considered in treating patients with mood and anxiety disorders. We also suggest that there is a need for long-term studies comparing the safety and efficacy of BDZs to newer ADs and antipsychotics.
Jitender Sareen and Murray B Stein

Rebuttals
Should the Prescription of BDZs Be Based on an Act of Faith?
M y esteemed colleagues and I agree that BDZs are a useful group of medications, and we do not seem to differ as to their short-term use. Dr Sareen and Dr Stein advocate for the long-term use of BDZs in treating mood and anxiety disorders, and, in support of their argument, they note that a reduction in the dose of BDZs may lead to symptomatic relapse, a small sample subset will develop dose escalation (tolerance or dependence?), and that BDZs are often better tolerated than SSRIs. So far, so good! My initial quandary starts with their fourth reason; that is, absence of recent evidence on the clinical usefulness of BDZs does not equal ineffectiveness . . . clinicians need to carefully consider the use of BDZs in the long-term management of mood and anxiety symptoms and researchers need to conduct large-scale RCTs.
Is the latter to be considered before the studies?
In the case of panic disorder, where standard professional guidelines consistently recommend the prescription of SSRIs over BDZs, Roy-Byrne et al 1 state that BDZs work rapidly but are restricted by their narrow range of efficacy across disorders, the risk of physiological dependence and withdrawal, and the risk of abuse. While the co-prescription of BDZs to anxious patients treated with ADs is common, "no placebocontrolled studies have yet been done . . . [on] the effectiveness of augmenting SSRIs with benzodiazepines." 1, p 1027 The same could be said about the treatment of comorbid anxiety and depression. Therefore, in summary, while there is evidence to support initial select co-prescription of BDZs with SSRIs, the wide open questions remain: For how long? And at what cost?
My second surprise is that in an argument about long-term treatment and, presumably, treatment resistance, the role of psychotherapy, and CBT in particular, is not mentioned. Surely, the long-term treatment of mood and anxiety disorders is not solely adequate pharmacology. Is not combined psychotherapeutic connection with the patient as important?
Lastly, as an addiction specialist, I am taken aback with the suggestion that anxiety could be a "BDZ-deficiency syndrome" similar to "diabetes and its insulin deficiency." While the incidence of dose escalation is relatively small in samples at low risk for addiction, this in no way negates the higher biopsychosocial risks of BDZ dependence and other substance misuses in anxious and (or) depressed patients, as evidenced by the recent large-scale epidemiologic studies of comorbidities. The vicious cycle between the misuse of drugs, including BDZs, and the occurrence of anxiety and (or) mood disorders is a common clinical presentation.
In summary, at issue is the risk-benefit analysis of the long-term prescription of BDZs in mood or anxiety disorders in the absence of adequate research. I fully support the search for newer medication with improved safety profiles. A careful risk analysis before the prescription of BDZs is required. CBT, as a widely studied and validated psychotherapeutic treatment, should also be considered as a first-line augmentation strategy or alternative to limited pharmacological response. The complexity of the withdrawal syndrome resulting from BDZ dependence precludes me to advocate their long-term prescription in the absence of adequate research. It should not be based on an act of faith!
Emerging Evidence That Risk of Fractures Is Not Only Associated With BDZs But Also Other Psychotropic Medications in the Elderly
W e thank Dr el-Guebaly for his thoughtful comments on the risks of BDZ use and his recommendations for methods to reduce these risks. We agree with many of his comments.
Specifically, we agree with Dr el-Guebaly that the risk of dose escalation and tolerance with BDZs is low. Nonetheless, physicians should prescribe these medications judiciously and in a responsible manner. There is also a need for further research to guide clinicians in understanding which patients are specifically at risk of dose escalation and abuse of BDZs. Anecdotally, we often have patients who are struggling with severe anxiety and report worry about becoming addicted to medications. In our experience, these patients are at low risk of abusing BDZs. Conversely, patients with anxiety disorders who have comorbid Cluster B personality traits, impulsivity, aggression, or somatization problems often do not do well with BDZs, in our experiences. In such patients, we prefer ADs and, if necessary, small doses of antipsychotics for management of anxiety symptoms.
We disagree with 2 specific points made by Dr el-Guebaly. First, Dr el-Guebaly mentions one of the common concerns about BDZs 1 is that they are associated with increased risk of falls in the elderly. We point to recent emerging data that show an association between SSRIs and risk for fractures. Also, a recent metaanalysis 2 examining the impact of 9 medication classes on falls in the elderly also shows that the increased risk for falls is not only associated with BDZs but also ADs and neuroleptics. Interestingly, in 1989 the state of New York changed policies such that BDZs would require triplicate prescriptions. This policy had a substantial impact on reducing the prescription of BDZs in New York. However, this reduction in prescriptions did not have an impact on the prevalence of hip fractures. 3 Although the latter study 3 used quasiexperimental data, and causal inferences cannot be inferred, these findings are interesting and suggest that BDZs may not be a strong contributor to falls in the elderly.
Second, Dr el-Guebaly comments that the APA guidelines on panic disorder, first edition, do not recommend the use of BDZs for the treatment of panic disorder. Please note that the updated guidelines published by the APA in 2009 4 recommend the use of BDZs in certain patients with panic disorder. These guidelines suggest that monotherapy with BDZs for panic disorder can be used when comorbid depression is not a major issue.
In summary, we believe that BDZs, when prescribed with full awareness of their risks and benefits, have an important role to play in the treatment of patients with mood and anxiety disorders.
